Predict your next investment

Venture Capital
thirdrockventures.com

See what CB Insights has to offer

Investments

165

Portfolio Exits

38

Funds

6

Partners & Customers

2

Service Providers

2

About Third Rock Ventures

Third Rock Ventures is a healthcare venture firm focusing on the areas of science and medicine to discover, launch and build companies that make a dramatic difference in people's lives.

Third Rock Ventures Headquarters Location

29 Newbury Street 3rd Floor

Boston, Massachusetts, 2116,

United States

617-585-2000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Third Rock Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Third Rock Ventures in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Third Rock Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Third Rock Ventures in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Third Rock Ventures News

Combined monogenic, polygenic risk prediction spurs changes in CAD management

Aug 17, 2022

Disclosures: Fahed reports receiving consultant fees from and owning shares in Goodpath. Khera reports being an employee of and holding equity in Verve Therapeutics; serving as a scientific advisor for Amgen, Color Health, Foresite Labs, Korro Bio, Maze Therapeutics, Navitor Pharmaceuticals, Novartis, Sarepta Therapeutics, Silence Therapeutics, Third Rock Ventures and Veritas International; receiving speaking fees from Amgen, Illumina, MedGenome and the Novartis Institute for Biomedical Research; and receiving a sponsored research agreement from IBM Research. Please see the study for all other authors’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio A combined monogenic and polygenic risk assessment for CAD can identify individuals at high inherited risk before overt manifestation of traditional risk factors, potentially improving clinician decision-making on preventive interventions. Clinical risk calculators such as the American College of Cardiology/American Heart Association Pooled Cohort Equations estimate 10-year atherosclerotic CVD risk to guide patient risk discussion around initiating statin therapy to lower LDL, Akl C. Fahed, MD, MPH, FACC, an interventional cardiologist and physician-scientist at Massachusetts General Hospital and instructor in medicine at Harvard Medical School, and colleagues wrote in JACC Advances. The researchers noted such risk calculators are dependent on the presence of clinical risk factors, such as hypertension or diabetes; CAD is a heritable disease, offering clinicians an opportunity to use genetic information to improve the identification of people at risk. Fahed is an interventional cardiologist and physician-scientist at Massachusetts General Hospital and instructor in medicine at Harvard Medical School. “Our study provides a framework for implementing combined monogenic and polygenic risk assessment for CAD in a preventive genomics setting,” Fahed told Healio. “By and large, participants found the risk assessment understandable and helpful, resulting in positive intent to make lifestyle changes. In 40% of cases, there was a change in clinical management following disclosure of genomic risk results.” Genetic sequencing, counseling on risk Fahed and colleagues analyzed data from 60 adults who attended an initial visit in a preventive genomics clinic and a disclosure visit to discuss results and recommendations, primarily via telemedicine, enrolled between December 2020 and August 2021. The mean age of participants was 51 years, 37% were women and 72% had no known CAD; half were referred by their cardiologists and half self-referred. Participants provided saliva samples at the clinic or remotely via a ship-to-home kit; they received low-coverage whole genome sequencing and a multi-gene, next-generation sequencing panel test from Color Health Inc. Polygenic score calculation was performed using a previously published score of CAD consisting of 6.6 million variants. Results were returned virtually or in person during a follow-up visit with a cardiologist and/or a genetic counselor. “During this visit, the clinicians disclosed the results of the test, discussed potential downstream implications and documented the results in the electronic medical record,” the researchers wrote. “Participants were then sent a monogenic test result report from the genetic testing company, a dedicated polygenic score report for CAD and a link to a polygenic score explainer website.” Researchers assessed digital post-disclosure surveys and conducted chart reviews to evaluate the impact of disclosure. Within the cohort, 3% had a monogenic variant pathogenic for familial hypercholesterolemia and 32% had a high polygenic score in the top quintile of the population distribution. In a post-disclosure survey, both the genetic test report (in 80% of participants) and the discussion with the clinician (in 89% of participants) were ranked as “very” or “extremely” helpful in understanding the result. Of the 42 participants without CAD, 40% had a change in management. “Despite the lack of clinical guidelines to initiate diagnostic or therapeutic interventions for CAD based on polygenic scores, physicians used the genetic test as an additional risk assessment tool in conjunction with clinical risk factors to guide additional interventions,” the researchers wrote. “Nearly half of participants without CAD had a change in management that fell into two categories. First, there were changes in pharmacotherapy, including the prescription or intensification of lipid-lowering medications to prevent or delay CAD development. Second, there were diagnostic coronary imaging scans to assess for existing coronary plaque or measure a coronary calcium score, both of which can potentially incentivize the initiation or intensification of lipid-lowering medication.” Combined testing ‘feasible and understandable’ The researchers found that changes in clinical management occurred more frequently in younger participants, including 70% of those aged 20 to 39 years, 39% of those aged 40 to 59 years and in 11.1% of those aged 60 years or older. There were no differences by sex or referral pathway. “In the context of CAD, our results suggest that combined testing of monogenic and polygenic drivers as part of a clinical visit is feasible and understandable to people,” the researchers wrote. “Testing also identified individuals who may benefit from preventive therapies or additional diagnostic testing resulting in a change in clinical management in participants at high inherited risk, especially when other clinical assessment tools failed to highlight their increased risk.” The researchers noted that participants were from a high educational and economic backgrounds and likely more engaged in preventive medicine; more research is needed with participants from underrepresented groups. Amit V. Khera “The findings from this study add another step in the direction towards clinical implementation of genomic risk assessment for CAD,” Amit V. Khera, MD, MSc, a physician-scientist at the Center for Genomic Medicine at Massachusetts General Hospital, told Healio. “To date, most studies on the clinical utility on polygenic scores leverage existing datasets, but there is growing need for prospective implementation studies to truly move towards clinical implementation.” For more information: Amit V. Khera, MD, MSc, can be reached at avkhera@mgh.harvard.edu. Twitter: @amitvkhera. Read more about

Third Rock Ventures Investments

165 Investments

Third Rock Ventures has made 165 investments. Their latest investment was in Terremoto Biosciences as part of their Series A on May 5, 2022.

CBI Logo

Third Rock Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/25/2022

Series A

Terremoto Biosciences

$75M

Yes

2

5/10/2022

Series B

MOMA Therapeutics

$150M

No

7

3/24/2022

Series B

Celsius Therapeutics

$83M

No

7

1/27/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/21/2021

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/25/2022

5/10/2022

3/24/2022

1/27/2022

12/21/2021

Round

Series A

Series B

Series B

Series A

Series A - II

Company

Terremoto Biosciences

MOMA Therapeutics

Celsius Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$75M

$150M

$83M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

7

7

10

10

Third Rock Ventures Portfolio Exits

38 Portfolio Exits

Third Rock Ventures has 38 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/22/2021

IPO

$99M

Public

10

4/14/2021

Acq - Pending

$99M

2

2/12/2021

IPO

$99M

Public

2

10/27/2020

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/24/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2021

4/14/2021

2/12/2021

10/27/2020

7/24/2020

Exit

IPO

Acq - Pending

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

10

2

2

10

10

Third Rock Ventures Fund History

6 Fund Histories

Third Rock Ventures has 6 funds, including Third Rock Ventures VI.

Closing Date

Fund

Fund Type

Status

Amount

Sources

6/15/2022

Third Rock Ventures VI

$1,100M

1

6/6/2019

Third Rock Ventures V

Subscribe to see more

Subscribe to see more

$99M

10

10/31/2016

Third Rock Ventures IV

Subscribe to see more

Subscribe to see more

$99M

10

3/25/2013

Third Rock Ventures III

Subscribe to see more

Subscribe to see more

$99M

10

8/31/2010

Third Rock Ventures II LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

6/15/2022

6/6/2019

10/31/2016

3/25/2013

8/31/2010

Fund

Third Rock Ventures VI

Third Rock Ventures V

Third Rock Ventures IV

Third Rock Ventures III

Third Rock Ventures II LP

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$1,100M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Third Rock Ventures Partners & Customers

2 Partners and customers

Third Rock Ventures has 2 strategic partners and customers. Third Rock Ventures recently partnered with American Cancer Society on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/14/2022

Partner

United States

Third Rock Ventures Teams Up With American Cancer Society’s Venture Fund.

The American Cancer Society 's venture-investment arm has formed a collaboration with venture firm Third Rock Ventures , as the society expands its use of venture capital to intensify its efforts in cancer research and provide services to patients .

1

11/25/2013

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

7/14/2022

11/25/2013

Type

Partner

Partner

Business Partner

Country

United States

United States

News Snippet

Third Rock Ventures Teams Up With American Cancer Society’s Venture Fund.

The American Cancer Society 's venture-investment arm has formed a collaboration with venture firm Third Rock Ventures , as the society expands its use of venture capital to intensify its efforts in cancer research and provide services to patients .

Subscribe to see more

Subscribe to see more

Sources

1

10

Third Rock Ventures Service Providers

2 Service Providers

Third Rock Ventures has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Series A

Management Consultants

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Series A

Provider Type

Management Consultants

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Third Rock Ventures Team

3 Team Members

Third Rock Ventures has 3 team members, including current Controller, Alison Connors.

Name

Work History

Title

Status

Philip Reilly

Founder

Current

Alison Connors

Controller

Current

Andrea Armstrong

Chief People Officer

Former

Name

Philip Reilly

Alison Connors

Andrea Armstrong

Work History

Title

Founder

Controller

Chief People Officer

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.